Disc Medicine Reports Positive Phase 2 Trial Results for DISC-3405 in Polycythemia Vera

Disc Medicine, Inc. announced positive initial results from its RESTORE-PV Phase 2 clinical trial of DISC-3405 for patients with polycythemia vera (PV). The data, presented on September 9, 2026, demonstrated that the drug effectively controlled hematocrit levels and significantly reduced the need for phlebotomy (blood removal).

Key Details

• Phlebotomy Reduction: In patients completing 26 weeks of the study (n=13), mean phlebotomy events significantly decreased from 4.0 in the 26 weeks at baseline to 0.6 post-treatment (p<0.0001).
• Phlebotomy-Free Rate: 61.5% of participants who completed 26 weeks remained entirely phlebotomy-free. Among a smaller group that completed a maintenance period (n=9), 77.8% were phlebotomy-free.
• Clinical Outcome: The treatment successfully maintained mean hematocrit levels below 45% through week 26 and was reported as generally well-tolerated.